Objectives: Hematological abnormalities, particularly lymphopenia, are common in patients with systemic lupus erythematosus (SLE), whether the disease is active or not. The aim of this study is to assess whether lymphopenia (blood counts 41000 K/ml) is a risk factor for severe infections in patients with SLE. Methods: A retrospective case-control study was performed. We reviewed the clinical records of 167 SLE patients throughout a 5-year period. SLE patients with severe infections were compared with those without infection and the presence of lymphopenia was obtained from the blood count previous to the infection date. Also, other clinical and laboratory features as well as immunosuppressive therapy and SLE disease activity index (SLEDAI) were recorded.
Introduction
Lymphopenia is a common hematological feature in patients with untreated systemic lupus erythematosus (SLE). 1, 2 . It has been associated with disease activity and has both prognostic and diagnostic implications. 3 Diverse immunological features have been related to the development of lymphopenia in SLE patients, including autoantibodies against surface molecules in lymphocytes, certain cytokines, opsonization and apoptosis, among others. [4] [5] [6] [7] Evidence suggests that lymphopenia per se is unable to trigger the development of autoimmune diseases. In fact, previous reports have revealed the requirement of other elements to develop an autoimmune 'environment' in conjunction with lymphopenia. Kuprika et al. 8 proposed the 'two-hit model', which supports the concept that lymphopenia causes temporal dysfunction of the mechanisms that are usually involved in the host's immunological tolerance. This causes proliferation of peripheral T cells, which, with an additional 'hit' (i.e. inflammation), could promote the development of autoimmune pathology. Therefore, even if lymphopenia does not cause autoimmune diseases by itself, it must be considered as part of the complex physiopathogenic model. 9 Furthermore, our group recently demonstrated that there are different abnormalities related to lymphopenia in T-lymphocyte subsets in SLE patients. 10 The aforementioned include quantitative and functional changes in activated T lymphocytes, regulatory T cells (Tregs) and Th17 cells. These findings suggest that lymphopenia is a risk factor for decrease in the number of Tregs through time. Also, it was found that when lymphopenia is present, a resistance toward suppression of the immune response by Tregs develops. This represents a breach in peripheral tolerance and could potentially perpetuate the development and maintenance of systemic autoimmune pathology.
On the other hand, infections represent one of the main causes of morbimortality in SLE patients 11 and are cause of death in up to 25% of cases. Their high prevalence and morbimortality has been attributed to the use of immunosuppressive agents 12 and the activity of the autoimmune disease itself. Also, there are reports in which other factors, such as neutropenia, are associated to infectious complications. 13 Regarding lymphopenia and infection risk, Ferreira et al.
14 found an association between persistently low CD4+ lymphocyte counts and opportunistic infections (cryptococcosis, aspergillosis, etc.). Also, prophylactic treatment with trimethoprim/sulfamethoxazole has been proposed for patients with lymphopenia in order to prevent infections with Pneumocystis jiroveci.
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The aim of this study was to evaluate the association between lymphopenia and the development of severe infections in SLE patients. Furthermore, other potential risk factors for these infections (SLE activity, immunosuppressive drugs and other laboratory anomalies) were assessed.
Methods
A retrospective case-control study was performed based on the clinical records. We included 167 patients with SLE diagnosis according to the ACR classification criteria 16 (89 cases and 78 controls). The data were collected from the institutional clinical records. We defined severe infection as at least 1 day of hospitalization and the use of intravenous antibiotics. The study period was from January 2005 to December 2010. Inclusion criteria for case study subjects were as follows: SLE diagnosis, complete clinical records, microbiologic isolation or unequivocal clinical data (i.e. cutaneous herpes zoster), patients 17 years or older and complete blood count (in 90-day period previous to the infection event). Controls were required to have the same characteristics, but without an infectious event during that period of time. All subjects were adjusted by age (AE5 years) and gender. Data were obtained from the same period during which the case subjects developed a severe infection (AE3 month range).
The data compilation included the following: subject (case or control), age (years), gender, time since SLE diagnosis (months), type of SLE activity (mucocutaneous, articular, renal, hematological, central nervous system and others), comorbidities, leukocyte count (with neutrophil and lymphocyte differential), period of time (days) from the complete blood count to hospitalization for severe infection, infection site, isolated microorganism, immunosuppressive therapy and dose, Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) (before and during the infectious event), 17 latest immunological test results (double-stranded DNA, anti-nucleosomes and complement levels), hospitalization length and date of the infection. Lymphopenia was defined according to the Systemic Lupus International Collaborating Clinics (SLICC) criteria as a lymphocyte count 41000 K/ml. 18 Double-stranded DNA (dsDNA) and antinucleosome antibody titers were measured by ELISA, and C3 and C4 levels were determined by spectrophotomery. The study was approved by the ethics institutional committee.
Statistical analysis
Variables were described as mean and standard deviation or proportions. Comparison between groups was made by chi-square test for categorical variables or Student's t-test. Odds ratio (OR) with 95% confidence interval (CI) was used to calculate association. To assess independent risk factors, multivariate analysis was performed by binary logistic regression model using a backward stepwise process. All variables with statistical significance in the univariate analysis or those that could have clinical relevance were included for the multivariate analysis. Tests for interaction among variables were also performed as part of the analysis. The goodness of fit of the model was evaluated by Hosmer and Lemeshow test.
The P-values considered significant were <0.05. Data were analyzed with support of the software SPSS v 15 (SPSS Inc., Chicago, IL, USA).
Results
We included 167 SLE patients, 89 cases and 78 controls. Clinical and demographic characteristics are depicted in Table 1 .
We found a higher proportion of patients with lymphopenia in cases in comparison to controls. Also, cases had higher SLEDAI score and prednisone (PDN) dose as well as lower C3 and C4 levels. None of the other variables show significant differences between groups (Table 1) .
In terms of isolated microorganism, the most frequently found bacteria were as follows: Escherichia coli (16%), Enterococcus sp (11%), Streptococcus pneumoniae (6%), Pseudomonas aeruginosa (6%), Staphylococcus aureus (6%), group A Salmonella (5%), Klebsiella pneumoniae (4%) and mycobacterias (4%). Acinetobacter baumanni and Cryptococcus neoformans were found two times each. The following microorganisms were found only once: Actinomyces sp, Adenovirus, Bacteroides fragilis, Candida glabrata, Citrobacter koseri, Enterobacter cloacae, Listeria monocytogenes, Morganella morganii, Pantoea agglomerans, Staphylococcus lugdunensi, Streptococcus pyogenes, Staphylococcus hominis and Streptococcus bovis. The main infection sites are shown in Table 2 .
According to univariate analysis, the variables that had a significant association with severe infections were as follows: lymphopenia, low complement levels (C4 and C3), high SLEDAI score as well as PDN and mycophenolate mofetil (MMF) treatment.
Interestingly, hydroxychloroquine (HCLQ) treatment was associated to decreased risk of severe infections (Table 3) .
The variables that were significant in the univariate analysis and those that could have significant clinical relevance were included in the multivariate analysis. The variables included in the binary logistic regression were as follows: lymphopenia, neutropenia, time since SLE diagnosis, high SLEDAI score, low C3 levels, low C4 levels, high anti-dsDNA antibody titers and immunosuppressive treatment. For the immunosuppressive treatment, we include in the analysis any immunosuppressive treatment, PDN, AZA (azathioprine), MMF, CFM (cyclophosphamide) and HCLQ treatments. Moreover, PDN treatment was further categorized as follows: none, low (<7.5 mg/day), moderate (7.5-30 mg/day) and high dose (30-100 mg/day).
After the multivariate analysis, lymphopenia (OR 5.2, 95% CI 2.39-11.3), PDN treatment (OR 4.8, 95% CI 2.1-11.9) and low levels of C3 (OR 2.97, 95% CI 1.1-7.9) remained as risk factors for the development of severe infections in SLE. Moreover, prednisone treatment, even at the lower dose (<7.5 mg/day), was associated with increased risk of severe infection. Interestingly, we did not find any association between the use of any other immunosuppressive drug (AZA, CFM, MMF and HCLQ) assessed and severe infections in our sample (Table 4) . No interaction was found between lymphopenia and any other variable.
Discussion
Since it has been proven that there are both qualitative and quantitative abnormalities in different Tcell subsets in SLE patients, the aim of the present work was to determine whether an abnormal lymphocyte count could be associated to the risk of severe infections in SLE patients. Our data show that lymphopenia, PDN treatment and low C3 levels are independent risk factors for the development of severe infections in SLE patients. Although there are in vitro studies that show that lymphopenia, one of the most frequent hematological features of SLE patients, is associated with alterations in the immune response, a direct relationship between lymphopenia and severe infections (being compared with patients without lymphopenia) had not been previously reported. In clinical practice, lymphopenia in SLE patients may also be associated to immunosuppressive therapy. 19 However, in this study we did not find any interaction between immunosuppressive drugs (PDN, AZA, MMF and CFM) and lymphopenia. Likewise, in the multivariate analysis, lymphopenia was the more relevant risk factor for the development of severe infections in our study group. Our results are in agreement with previous reports 20 that have shown that lower counts of lymphocytes at SLE diagnosis or along different time points confer increased risk of infections. However, these reports are more related to opportunistic infections as the outcome. We found that almost half of our patients (49.4%) with severe infections had genitourinary or skin/soft tissue involvement. Interestingly, a high percentage of patients (23%) developed infections related to high mortality (almost 20%) (bacteremia, central nervous system and disseminated infections), [21] [22] [23] [24] suggesting that these patients may be the target of lethal infections. Most of the isolated microorganisms were bacteria, and it is important to make emphasis on the fact that >5% of them were highly virulent (P. aeruginosa, A. baumanni and C. glabrata, among others). Mycobacteria were also relatively common, as it has been described in previous SLE cohorts. 25 This study was not designed to identify the lymphocyte subset that is affected in lymphopenia, but it can be inferred, based on previous findings, the isolated microorganisms, and according to our hypothesis, that there are important abnormalities (both qualitative and quantitative) regarding different T-cell subsets, such as Tregs, which have been Bold numbers represent significant P-values < 0.05. found to be deficient and might be involved in the increased vulnerability to some bacterial infections. Interestingly, Th17 cells are one of the main physiological responders to fungal infections. Moreover, it has been widely shown that Th17 cells are expanded in SLE patients; however, our data might suggest the idea that in SLE, this subset is deficient regarding its response upon fungal infections. 26 Likewise, glucocorticoids have been found to be one of the most important drugs related to such infections, in a dose-dependent manner, 27, 28 which is in agreement to our results. In our study, most patients who developed a severe infection were under immunosuppressive treatment (92%), with glucocorticoids being a part of the regime in 93% of them. Moreover, mean PDN dose in the cases was moderate (22 mg/day); however, the multivariate analysis shows that the increased risk of severe infection was present even in the lower dose group (<7.5 mg/day).
Furthermore, 30% of patients had antimalarials as part of their treatment. These drugs have a significant antibiotic effect, 29 and there are previous studies that demonstrate they can be protective against infections in SLE patients. 30 However, in our study, this association was not confirmed in the multivariate analysis. Interestingly, none of the other immunosuppressive treatments assessed (AZA, CFM and MMF) was associated to increased risk of severe infections, which highlights the relevance of PDN as the most important immunosuppressive drug in terms of risk of severe infections in SLE.
SLEDAI is a useful, validated tool to evaluate SLE disease activity. Interestingly, SLEDAI does not include lymphopenia as a marker of disease activity (only leukopenia and thrombocytopenia), even though it is included as part of the hematological ACR criteria for SLE classification. However, previous data suggest the role of lymphopenia as part of disease activity. 4 Our results show that disease activity is not an independent risk factor for the development of severe infections and suggest that lymphopenia could provide additional and more precise information about relevant immunological alterations that increase the risk of severe infections, without regarding disease activity.
Low complement (C3) levels were another risk factor for severe infections in our study. Complement is an important component of innate immune system, and it plays a relevant role in the regulation of the adaptative immune system, including T-lymphocyte response against certain bacteria. 31, 32 Association between low levels of C3 and risk of severe infections has been currently related to abnormalities not only in T-cell responses but also in natural killer cells' number. 33 Hence, it would be of interest to corroborate this association in further studies involving SLE patients.
In 2006, Ng et al. 20 described 91 Chinese patients with early SLE (<1 year from diagnosis) and lymphopenia as a risk factor for infections. As far as we know, our study is the first to show an association between lymphopenia and the risk for severe infections in SLE patients with diverse stages and activities of the disease. Our findings suggest that lymphopenia in SLE confers a higher risk for severe infections, without regarding clinical or serological activity. Hence, active or remission patients with lymphopenia are at increased risk for severe infections. All of these findings should be corroborated in prospective studies, but they should also open new research lines based on the study of the molecular mechanisms associated to lymphopenia in SLE and other autoimmune diseases in which lymphopenia is also a significant finding, such as Sjö gren's syndrome, mixed connective tissue disease and inflammatory myopathies. The main limitations of our study are the ones related to the retrospective collection of data. Susceptibility to infections has been related also to different ethnic backgrounds, so our data could be limited to this background. In summary, our data support the role of lymphopenia as an independent risk factor for severe infections in SLE patients. Hence, we suggest that specific recommendations for diagnosis and treatment, such as adjustments in immunosuppressive therapy, vaccination and use of prophylactic antibiotics should be made for SLE patients with lymphopenia.
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